Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01)-MedSci.cn

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01)

Yoshino, T; Di Bartolomeo, M; Raghav, KPS; Masuishi, T; Kawakami, H; Yamaguchi, K; Nishina, T; Wainberg, ZA; Elez, E; Rodriguez, J; Fakih, M; Ciardiello, F; Saxena, K; Kobayashi, K; Bako, E; Okuda, Y; Meinhardt, G; Grothey, A; Siena, S

JOURNAL OF CLINICAL ONCOLOGY, 2022; 40 (4):

科室
- - 订阅+
  - 更多科室
工具
服务